Answers are grounded in this paper and cite their sources.
Pilot study demonstrates effective SARS-CoV-2 detection in saliva samples, suggesting rapid antigen tests can reliably identify variants with higher oral viral shedding.
We conducted a pilot study to determine if the BinaxNOW rapid antigen test can detect SARS-CoV-2 antigen in saliva, in place of the specified nasal (Nares) swab sample. A nasal swab may not provide an optimal sample for detecting Omicron, now the predominant variant, because Omicron sheds a greater viral load into saliva than into the nasal passages. Saliva was obtained from non-infected donors, spiked with varying concentrations of heat-denatured SARS-CoV-2 virus, and tested using the BinaxNOW kit following the manufacturer’s instructions. The BinaxNOW test detected COVID-19 in saliva samples with a Limit of Detection (LOD) of 178 TCID 50 /mL saliva, which was the lowest concentration tested. This detection sensitivity is comparable to the LOD reported by the manufacturer for BinaxNOW (140.6 TCID 50 /mL) using nasal samples. This result shows that the BinaxNOW test can detect SARS-CoV-2 in saliva with a detection power comparable to that obtained using nasal swab samples.
No takes yet. Share an insight, caveat, or question.
Chomczynski et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: